Get the latest tech news
A once-monthly jab cuts body weight by 16% in groundbreaking obesity trial
A new drug from California-based pharma company Amgen, which has concluded a phase II trial, shows promise as a powerful treatment for obesity. With just a once-monthly shot of 'MariTide,' participants in the study lost as much as 16% of their body weight over the course of a year.
By contrast, a monthly dosage is easier to stick with, and can potentially be made available more easily to patients in remote areas where medical supplies are delivered less frequently. The phase 2 trial saw 592 participants aged over 18 and with a body mass index or BMI (the weight in kilograms divided by the square of the height in meters) higher than 30. The results are rather encouraging: obese participants in the experimental group who received an injection of the treatment every four weeks were found, on average, to have lost between 12.3% to 16.2% of their body weight at the end of a year.
Or read this on r/tech
